Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers
Clinical Transplantation · 2023
DOI: 10.1111/ctr.14893 ↗At a glance
Journal article in Clinical Transplantation, 2023. Written by Kevin A Reininger and 13 co-authors. Institution: Department of Pharmacy, Hennepin County Medical Center, Minneapolis, Minnesota, USA. Major MEDLINE topics: Tacrolimus, Kidney Transplantation. Cited 11 times so far (Crossref); 36 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS.
Abstract (original language)
Kidney transplant recipients carrying the CYP3A5*1 allele have lower tacrolimus troughs, and higher dose requirements compared to those with the CYP3A5*3/*3 genotype. However, data on the effect of CYP3A5 alleles on post‐transplant tacrolimus management are lacking. The effect of CYP3A5 metabolism phenotypes on the number of tacrolimus dose adjustments and troughs in the first 6 months post‐transplant was evaluated in 78 recipients (64% Caucasians). Time to first therapeutic concentration, percentage of time in therapeutic range (TTR), and estimated glomerular filtration rate (eGFR) were also evaluated. Fifty‐five kidney transplant recipients were CYP3A5 poor metabolizers (PM), 17 were intermediate metabolizers (IM), and 6 were extensive metabolizers (EM). Compared to PMs, EMs/IMs had significantly more dose adjustments (6.1 vs. 8.1, p = .015). Overall, 33.82% of trough measurements resulted in a dose change. There was no difference in the number of tacrolimus trough measurements between PMs and EM/IMs. The total daily tacrolimus dose requirements were higher in EMs and IMs compared to PMs (
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
- Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
- Division of Nephrology, Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of Nephrology, University of Nebraska, Omaha, Nebraska, USA.
ORCID profiles: Kevin A Reininger, Guillaume Onyeaghala, Teresa Anderson-Haag, David S Schladt, Baolin Wu, Weihua Guan, Casey R Dorr, Rory P Remmel, Roslyn Mannon, Arthur J Matas, William S Oetting, Paul Stahler, Ajay K Israni, Pamala A Jacobson
Funding
- NIAID NIH HHS
Cite
APA
Reininger, K. A., Onyeaghala, G., Anderson-Haag, T., Schladt, D. S., Wu, B., Guan, W., Dorr, C. R., Remmel, R. P., Mannon, R., Matas, A. J., Oetting, W. S., Stahler, P., Israni, A. K., & Jacobson, P. A. (2023). Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers. Clinical Transplantation. https://doi.org/10.1111/ctr.14893
Vancouver
Reininger KA, Onyeaghala G, Anderson-Haag T, Schladt DS, Wu B, Guan W, et al. Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers. Clinical Transplantation. 2023. doi:10.1111/ctr.14893
BibTeX
@article{Reininger2023,
author = {Reininger, Kevin A and Onyeaghala, Guillaume and Anderson-Haag, Teresa and Schladt, David S and Wu, Baolin and Guan, Weihua and Dorr, Casey R and Remmel, Rory P and Mannon, Roslyn and Matas, Arthur J and Oetting, William S and Stahler, Paul and Israni, Ajay K and Jacobson, Pamala A},
title = {Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.14893}
}
EUVIMED